



Phospho-GSK3 alpha (Ser21) Polyclonal Antibody

Product Details		
Size	100 μL	
Species Reactivity	Human	
Host/Isotype	Rabbit / IgG	
Class	Polyclonal	
Туре	Antibody	
Conjugate	Unconjugated	
Immunogen	A synthetic phosphorylated peptide around S21 of human GSK3alpha (NP_0639372)	
Form	Liquid	
Concentration	0.82 mg/mL	
Purification	Affinity Chromatography	
Storage buffer	PBS, pH 7.3, with 50% glycerol	
Contains	0.05% ProClin 300	
Storage conditions	-20° C, Avoid Freeze/Thaw Cycles	
RRID	AB_2914863	


Applications	Tested Dilution	Publications
Western Blot (WB)	1:500-1:2,000	-
Immunoprecipitation (IP)	1:50-1:100	-

Product Specific Information

Positive test controls include: 293, HeLa.


Immunogen sequence: TSSFA

Product Images For Phospho-GSK3 alpha (Ser21) Polyclonal Antibody




Phospho-GSK3 alpha (Ser21) Antibody (PA5-121291) in WB

Western blot analysis of Phospho-GSK3 alpha (Ser21) in extracts of 293 and HeLa cells. Samples were incubated with Phospho-GSK3 alpha (Ser21) Polyclonal antibody (Product # PA5-121291) using a dilution of 1:1,000, followed by HRP Goat Anti-Rabbit IgG (H+L) secondary antibody at a dilution of 1:10,000. 293 cells were treated by Insulin (100 nM) for 10 minutes after serum-starvation overnight. HeLa cells were treated by Insulin (0.01 U/mL) for 15 minutes after serum-starvation overnight. Lysates/proteins: 25 µg per lane. Blocking buffer: 3% BSA.



Phospho-GSK3 alpha (Ser21) Antibody (PA5-121291) in WB

Western blot analysis of Phospho-GSK3 alpha (Ser21) in extracts of 293 cells. Samples were incubated with Phospho-GSK3 alpha (Ser21) Polyclonal antibody (Product # PA5-121291) using a dilution of 1:1,000 or GSK3 alpha antibody (Product # PA5-87470). Followed by HRP Goat Anti-Rabbit IgG (H+L) secondary antibody at a dilution of 1:10,000. 293 cells were treated by Insulin (100 nM) for 10 minutes after serum-starvation overnight. Lysates/proteins: 25 µg per lane. Blocking buffer: 3% BSA.



Phospho-GSK3 alpha (Ser21) Antibody (PA5-121291) in IP

Immunoprecipitation of Phospho-GSK3 alpha (Ser21) in 200 g extracts of 293T cells. Samples were precipitated with 3 g Phospho-GSK3 alpha (Ser21) Polyclonal antibody (Product # PA5-121291). Western blot was performed from the immunoprecipitate using Phospho-GSK3 alpha (Ser21) Polyclonal antibody (Product # PA5-121291) at a dilution of 1:1,000.

For research use of missing sackage increasors. Not for research without express authorization, Products are warranted to operate or perform substantially in conformance with published recompanying package interest ("Documentation"). No claim of suitability for use in applications regulated by FDA is made. The warranty provided herein is valid only byhen used by properly trained individuals. Ninelses otherwise stated in the Documentation, this warranty is immided to one year from date of shipment when the Product is subjected to normal, proper and intended usage. This warranty is limited to one year from date of shipment when the Product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample furnished to Buyer is merely illustrative of the general type and quality of goods and does not represent that any Product will conform to such model or sample. No OTHER WARRANTIES, EXPRESS OR IMPLED, ARE GRANTED INCLUDING WITHOUT LIMITATION, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, OR NON INFRINGEMENT.

BUYER'S EXCLUSIVE REMEDY FOR NON-CONFORMING PRODUCTS DURING THE WARRANTY PERIOD IS LIMITED TO REPAIR, REPLACEMENT OF OR REFUND FOR THE NON-CONFORMING PRODUCT(S) AT SELLER'S SOLE OPTION. THERE IS NO BOLIGATION TO REPAIR, REPLACEMENT OF OR REFUND FOR THE NON-CONFORMING PRODUCT(S) AT SELLER'S SOLE OPTION. THERE IS NO BOLIGATION TO REPAIR, REPLACEMENT OF OR REFUND FOR THE NON-CONFORMING PRODUCT(S) AT SELLER'S SOLE OPTION. THERE IS NO BOLIGATION TO REPAIR, REPLACEMENT OF OR REFUND FOR THE RODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS. Unless otherwise expressly st